162 result(s)
GSK Medical
This online medical resource for scientific and clinical information is intended to share the latest development in clinical research on GSK Products
Asthma | Unmet Needs
Asthma remains a serious health risk in the US1. In this section you will find information on the unmet need for more effective asthma treatments for the many patients still experiencing burdensome symptoms despite ICS/LABA treatment.
GSK Medical | Pipeline
Strengthening our R&D pipeline through a focus on science related to the immune system, the use of the human genetics, and advanced technologies
Inhaled molecules for COPD treatment
How does molecule pharmacology correlate with clinical efficacy and safety?
Inhalers in Respiratory Medicine
The Link Between the Molecules and the Patient
The EMAX Trial
Explore the evidence for initial maintenance treatment with dual bronchodilators compared with bronchodilator monotherapy
COPD
Our website is dedicated to providing you with the highest quality scientific information surrounding the treatment and clinical management of COPD.
Vaccines
GSK Vaccines Medical
Educational Webinars (*Stand Alone*)
View disease educational resources from GSK oncology
Mechanism of Disease
View material from GSK oncology on proposed, mechanism of disease of various cancers.
Mechanism of Disease
View material from GSK oncology on proposed, mechanism of disease of various cancers.
Educational Webinars old
View videos from GSK oncology on mechanism of disease as well as other disease education resources.
Educational Webinars
View disease educational resources from GSK oncology
Asthma | Home
Our website is dedicated to providing you with the highest quality scientific information surrounding the treatment and clinical management of moderate to severe asthma, delivered in response to your questions.
Disease Information
View videos from GSK oncology on mechanism of disease as well as other disease education resources.
Oncology
This area of the website is intended for HCPs specializing in Oncology. GSK does not support or endorse any use of its products that is not consistent with the approved prescribing information in the official product monograph
GSK at Conferences
GSK Oncology will have a presence at these meetings. Please visit us at our scientific booth or view our scientific information
Congress Presentations
View congress posters and presentations from GSK oncology to learn about the latest developments in clinical research on GSK oncology products.
Pipeline
Our unique R&D approach of Science x Technology x Culture is helping to fight cancer on multiple groundbreaking fronts – focusing on maximizing survival through the discovery and development of novel oncology medicines that may have life-changing potential.
Resource Links
View resources from medical organizations, patient advocacy organizations as well as global and local guidelines.
Patient Empowerment Alliance
Learn about the Patient Empowerment Alliance (P.E.A.), an innovative part of the GSK Supported Studies Program.
Severe Asthma
Eosinophilic airway inflammation severe asthma
Asthma | Role of LAMA
What is the role of LAMA?
Commonly Asked Questions
Using data from the CAPTAIN study, Professor Barnes and Dr Leather answer common questions about the role of LAMA in the treatment of asthma…
Asthma | Role of LAMA
How is LAMA positioned in the GINA guidelines?
Asthma | Use of Triple Therapy
CAPTAIN informs on which treatment is best suited to which patient in moderate to severe asthma..
Asthma | Use of Triple Therapy
CAPTAIN provides robust evidence to support, and better tailor, the use of FF 100/UMEC/VI and FF 200/UMEC/VI using a treatable traits based approach
Asthma | Use of Triple Therapy
Relative to other studies investigating triple therapy in asthma, CAPTAIN inclusion criteria were intentionally broadened to capture the heterogeneity of uncontrolled asthma seen in real-world clinical practice, with no requirement for a history of exacerbations
Asthma | Use of Triple Therapy
The CHEST 2022 Annual Meeting took place 16–19 October 2022 in Nashville, Tennessee, United States.
Asthma | Use of Triple Therapy
The CHEST 2023 Annual Meeting took place October 8–11 October 2023 in Honolulu, Hawai’i, United States.
Asthma | Use of Triple Therapy
CAPTAIN helps to identify which treatment for which patient in moderate to severe asthma
Asthma | Use of Triple Therapy
The CAPTAIN study provides robust evidence to support, and better tailor, the use of triple therapy using a treatable-traits-based approach. In this section you will find more information on how the CAPTAIN study supports the use of triple therapy in asthma.
ERS 2023 International Congress Asthma Highlights
The ERS 2023 international congress took place 9–13 September 2023 in Milan, Italy.
ERS 2022 Congress asthma highlights
The ERS 2022 international conference took place this year between September 4–6 in Barcelona, Spain.
Asthma | Broader Perspectives
LAMA can be used as an add-on to both medium-dose ICS/LABA combination and also to high-dose ICS/LABA combination. Addition of LAMA decreases the risk for exacerbation, improves the lung function, and also improves asthma symptom control in these patients.
Asthma | Broader Perspectives
Assessment tools are available and can be simple to use: objective assessments (e.g. spirometry) and subjective assessments (e.g. GINA questions, APGAR and ACT validated tools) should be incorporated into routine asthma patient management in primary care. They are important tools to diagnose and assess severity of asthma, and also for the assessment of response to therapy. Asthma patient management is a continuous process with assessment, adjustment of therapy, treating comorbidities, and assessing treatment response.
Asthma | Broader Perspectives
The AMCP-NEXUS 2022 National Meeting took place 11–14 October 2022 in National Harbour, Maryland, United States.
Asthma Forward | Broader Perspectives
The ATS 2023 international conference took place between May 19–24, 2023 in Washington DC, USA.
Asthma | Broader Perspectives
The ATS 2022 International Conference took place 13–18 May 2022 in San Francisco, California, United States, showcasing breakthrough innovations in science and patient care in respiratory and pulmonary fields.
Asthma | Broader Perspectives
Guidance-based care of uncontrolled asthma despite ICS/LABA requires an individualized approach; it is now possible to personalize medications according to individual patient needs based on the MoA of each medication.
Asthma | Broader Perspectives
Guidance-based care of uncontrolled asthma despite ICS/LABA requires an individualised approach. In this section you will find information on the practical considerations for step-up therapy in asthma.
Risk Factors and Clinical Burden of RSV in Older Adults
While RSV-related infections usually present as mild cold-like symptoms in adults, some cases may lead to more serious respiratory complications, hospitalization and death, particularly in older adults and those with underlying conditions1
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is an important cause of respiratory illness in all ages, including vulnerable adults. Learn about RSV and the associated disease in adults.1
Patient management
Treatment options for herpes zoster are suboptimal and may have limited efficacy and poor tolerability in some patients. Therefore, improvements are needed in the prevention and management of herpes zoster.1,2
Prevention through vaccination: The ZOE programme - RZV pivotal and extension studies in individuals over 50 years of age
The efficacy of the Recombinant Zoster Vaccine (RZV) was evaluated in two Phase 3 clinical trials, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50, NCT01165177) and Zoster Efficacy Study in Adults 70 Years of Age or Older (ZOE-70, NCT01165229).1,2 The Zoster-049 study (NCT02723773) is an ongoing long-term follow-up (LTFU) study of the ZOE-50 and ZOE-70 studies.3,4
Real-world evidence for the recombinant zoster vaccine (RZV)
Since the first approval of the recombinant zoster vaccine (RZV) against herpes zoster (HZ) in 2017, evidence for its use in real-world settings has been generated through real-world studies.
Burden of disease and complications
Burden of disease and complications
Epidemiology and risk factors
Herpes zoster is caused by the reactivation of the varicella zoster virus.
Prevention through vaccination: Immunocompromised patients
Efficacy, immunogenicity, and safety of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised subjects
Herpes Zoster
Herpes zoster, also known as shingles, is a painful condition caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.1-4
Disease Information
View disease information content from GSK Vaccines
Vaccines
GSK Vaccines Medical
Vaccine Virtual Days 2023 On demand
Vaccine Virtual Days 2023 now available on demand
GSK Vaccines Medical Affairs | Vaccine Virtual Days 2022
Vaccine Virtual Days 2022 March 30th and 31st, 2022 Let science guide the way
GSKpro XX | VVD4 2023 overview for Healthcare Professionals
GSKpro is exclusively created for healthcare professionals to provide GSK product related information, services and support.
GSK Vaccines Medical Affairs | Vaccine Virtual Days 2022
Vaccine Virtual Days 2022 March 30th & 31st Let science guide the way
Conferences
Please visit scientific meetings and events where GSK Vaccines will have a presence
GSK Vaccines Medical Affairs | Congress Presentations | Vaccine Virtual Days 2022
Vaccine Virtual Days 2022 Let science guide the way
Congress Presentations
View congress posters and presentations from GSK Vaccines
Resources
View resources from medical organizations, patient advocacy organizations as well as global and local guidelines.
Respiratory
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus augue nunc, quis consectetur tortor malesuada at curabitur. Dolor sit amet, consectetur adipiscing elit. Maecenas rhoncus aug nunc, quis consectetur tortor malesuada at curabitur.
Summary - Anoro
For UMEC/VI the NMA showed outcome benefits compared with other single-inhaler LAMA/LABA dual therapies and monotherapies¹
Network meta-analysis (NMA) - Anoro
Comparing efficacy of dual therapies among patients with COPD
NMA class comparison data in COPD
FF/UMEC/VI versus triple and dual bronchodilator therapies
Summary
For FF/UMEC/VI, the NMA suggest favourable efficacy compared with other single-inhaler triple therapies.1
NMA class comparison data in COPD - Anoro
UMEC/VI versus dual and mono-bronchodilator therapies
Network meta-analysis (NMA)
Comparing efficacy of triple therapies among patients with COPD
Clinical Efficacy
As well as ease of use, and having a low number of errors with an inhaler, patients need treatments that show clinical efficacy.
Technical Performance
Explore the technical performance of inhalers
Summary
Summary
Patient Benefits
What are the key considerations affecting inhaler choice, from a patient and physician perspective?
Unmet Need
In this section the symptom burden and unmet needs of patients with COPD are discussed, as well as the importance of correct inhaler technique and the impact of multiple inhaler therapy.
Asthma | Use of Triple Therapy
What is the CAPTAIN study? CAPTAIN study provides evidence to support tailoring of asthma treatment based on symptom and risk assessment.
Asthma | Unmet Needs
Why do we need better treatment?
Asthma | Unmet needs
The 63rd Annual Meeting of the Japanese Respiratory Society took place 28–30 April 2023 in Tokyo, Japan.
Asthma | Unmet Needs
Asthma remains a serious health risk in the US1. In this section you will find information on the unmet need for more effective asthma treatments for the many patients still experiencing burdensome symptoms despite ICS/LABA treatment.
Asthma | Unmet Needs
Asthma is a heterogeneous disease and its management is multifactorial; many patients often remained uncontrolled despite treatment. HCPs have a critical role in identifying and managing patients who are not adequately controlled, which involves:
Asthma | Unmet Needs
Which treatments should be considered when patients have inadequately controlled asthma on ICS/LABA?
Asthma | Unmet Needs
Asthma remains a serious health risk in the US1. In this section you will find information on the unmet need for more effective asthma treatments for the many patients still experiencing burdensome symptoms despite ICS/LABA treatment.
Asthma | Role of LAMA
LAMAs have an important role in tackling undertreated bronchoconstriction in asthma. In this section you will find more information on the role of LAMA and how combining ICS/LABA/LAMA therapies provides dual bronchodilation and promotes an anti-inflammatory effect in the airways.
Asthma | Home
Our website is dedicated to providing you with the highest quality scientific information surrounding the treatment and clinical management of moderate to severe asthma, delivered in response to your questions.
Conferences
Please visit scientific meetings and events where GSK Vaccines will have a presence
GSK Medical | Pipeline
Strengthening our R&D pipeline through a focus on science related to the immune system, the use of the human genetics, and advanced technologies
Co-administration of the recombinant zoster vaccine (RZV) with other adult vaccines
Throughout life, vaccines are recommended to protect individuals from vaccine-preventable diseases.
Load more
Thank you for query. We are sorry, but we did not find information about this topic:
Here are some steps that you can take to improve the accuracy of your search:
- Check the spelling of your search.
- Try a different wording.
- Reset or review the filters applied (if filters were used to perform this search).
- Check the accuracy of your search terms.
- Try using multiple keywords to narrow down your search.
- Try using synonyms or related words to broaden your search.